{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:27:24Z","timestamp":1793766444627,"version":"4.6.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clgc.2026.102650","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T15:38:43Z","timestamp":1786721923000},"page":"102650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Utility of Circulating Tumor DNA as a Monitoring Tool for Marker-Negative Germ Cell Tumors and Somatic Type Malignancies"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1534-5397","authenticated-orcid":false,"given":"Zachariah","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Glover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9821-8662","authenticated-orcid":false,"given":"Andrew C.","family":"Johns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3379-2644","authenticated-orcid":false,"given":"Emanuele","family":"Crupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2490-4453","authenticated-orcid":false,"given":"John","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amishi Y.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Jad","family":"Moussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2459-1875","authenticated-orcid":false,"given":"Cindy Y.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6027-8774","authenticated-orcid":false,"given":"John F.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7697-9591","authenticated-orcid":false,"given":"Jose A.","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne L.","family":"Hofstetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungtaek L.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6034-8939","authenticated-orcid":false,"given":"Yago L.","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Alhalabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1915-4491","authenticated-orcid":false,"given":"Matthew T.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.clgc.2026.102650_bib0001","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant Atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.clgc.2026.102650_bib0002","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102650_bib0003","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1200\/PO.20.00321","article-title":"Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy","volume":"5","author":"Thompson","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2026.102650_bib0004","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1158\/1078-0432.CCR-19-3467","article-title":"Serial ctDNA monitoring to predict response to systemic therapy in metastatic gastrointestinal cancers","volume":"26","author":"Parikh","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.clgc.2026.102650_bib0005","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jamaoncol.2017.5332","article-title":"Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies","volume":"4","author":"Lee","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102650_bib0006","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.euo.2023.05.012","article-title":"Circulating tumor DNA as a predictive and prognostic biomarker in the perioperative treatment of muscle-invasive bladder cancer: a systematic review","volume":"7","author":"Crupi","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2026.102650_bib0007","article-title":"Longitudinal evaluation of circulating tumor DNA as a prognostic biomarker to detect molecular residual disease in germ cell tumors","volume":"9","author":"Hassoun","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102650_bib0008","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/bju.16926","article-title":"Clinical utility of tumour-informed circulating tumour DNA in patients with testicular cancer","volume":"136","author":"Ben-David","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2026.102650_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103224","article-title":"Serum tumour markers in germ cell tumours: from diagnosis to cure","volume":"159","author":"Pedrazzoli","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102650_bib0010","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1002\/1097-0142(19811115)48:10<2274::AID-CNCR2820481024>3.0.CO;2-W","article-title":"Lactic dehydrogenase in the monitoring and prognosis of testicular cancer","volume":"48","author":"Lippert","year":"1981","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2026.102650_bib0011","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2020.10.024","article-title":"Integrated expression of circulating miR375 and miR371 to identify teratoma and active germ cell malignancy components in malignant germ cell tumors","volume":"79","author":"Nappi","year":"2021","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102650_bib0012","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40291-021-00521-x","article-title":"The diagnostic accuracy of miR-371a-3p for testicular germ cell tumors: a systematic review and meta-analysis","volume":"25","author":"Liu","year":"2021","journal-title":"Mol Diagn Ther"},{"issue":"3","key":"10.1016\/j.clgc.2026.102650_bib0013","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.euo.2023.10.021","article-title":"Evaluation of a miRNA-371a-3p assay for predicting final histopathology in patients undergoing primary nerve-sparing retroperitoneal lymphadenectomy for stage IIA\/B seminoma or nonseminoma","volume":"7","author":"Seelemeyer","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clgc.2026.102650_bib0014","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.3142","article-title":"Clinical performance of Signatera Genome assay in a cohort of patients (pts) with solid tumors","volume":"43","author":"George","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102650_bib0015","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2026.102650_bib0016","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.1996.14.2.454","article-title":"Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center","volume":"14","author":"Puc","year":"1996","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102650_bib0017","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1200\/JCO.1989.7.10.1497","article-title":"Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience","volume":"7","author":"Schultz","year":"1989","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102650_bib0018","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0022-5347(05)64275-9","article-title":"Management of post-chemotherapy residual masses in advanced seminoma","volume":"168","author":"Flechon","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2026.102650_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"9","key":"10.1016\/j.clgc.2026.102650_bib0020","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.clgc.2026.102650_bib0021","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.juro.2015.12.082","article-title":"Treatment and clinical outcomes of patients with teratoma with somatic-type malignant transformation: an international collaboration","volume":"196","author":"Giannatempo","year":"2016","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102650_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2026.102616","article-title":"Teratoma-specific assay design enables detection of circulating tumor DNA in post-chemotherapy residual retroperitoneal disease","volume":"24","author":"Ito","year":"2026","journal-title":"Clin Genitourin Cancer"},{"issue":"9","key":"10.1016\/j.clgc.2026.102650_bib0023","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1302\/2046-3758.109.BJR-2021-0014.R1","article-title":"Detection and utility of cell-free and circulating tumour DNA in bone and soft-tissue sarcomas","volume":"10","author":"Tsoi","year":"2021","journal-title":"Bone Jt Res"},{"key":"10.1016\/j.clgc.2026.102650_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2026.03.018","article-title":"Diagnostic accuracy of circulating tumor DNA to predict retroperitoneal histology in patients treated with retroperitoneal lymph node dissection for testicular germ tumor","author":"Thakker","year":"2026","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102650_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2026.102567","article-title":"Circulating tumor DNA as a novel indicator of teratoma in nonseminomatous germ cell tumor","volume":"24","author":"Ito","year":"2026","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2026.102650_bib0026","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41379-020-00668-8","article-title":"Methylation profiles of imprinted genes are distinct between mature ovarian teratoma, complete hydatidiform mole, and extragonadal mature teratoma","volume":"34","author":"Kato","year":"2021","journal-title":"Mod Pathol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:16:10Z","timestamp":1793765770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1558767326001503"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102650","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utility of Circulating Tumor DNA as a Monitoring Tool for Marker-Negative Germ Cell Tumors and Somatic Type Malignancies","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102650","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102650"}}